PE-22-28 for Health & Longevity

Created on 11/14/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

PE-22-28 is a laboratory-made seven-amino-acid peptide, sold as a research chemical, built to block a potassium channel that keeps nerve cells quiet, with mood as the intended target. Everything known comes from cells and mice; no study in people has been published or registered, and no safety work exists in any species. It stands as a laboratory hypothesis rather than a usable one. (Full Review)

Protocol

Published four-day regimen
3.0 micrograms per kilogram intraperitoneally once daily for four days
Mouse schedule under which neurogenesis and behavioral change were measured; 1 mg/kg by oral tube feeding remained active in the same test
Published regimen, acute
Single 3.0–4.0 micrograms per kilogram intraperitoneal dose in mice
The amount used in the forced swim test; a rodent laboratory dose, no validated human equivalent exists
Route
Intraperitoneal injection
All published work used it, with one oral gavage comparison; a laboratory animal route, not used in people outside specific clinical procedures
Time to effect
Depression-related behavior
Within hours in mice
A single dose altered behavior within hours
Neurogenesis markers
Four days in mice
Four days changed neurogenesis markers
Time to effect in humans
Unknown
No human time course has been measured

Benefits

Contraindications
  • Anyone with epilepsy or a prior unprovoked seizure
  • Anyone with prior ischemic stroke or transient ischemic attack
  • Anyone with sinus node disease, bradycardia (resting heart rate below 50 beats per minute) or unexplained syncope
  • Anyone with an inherited channel disorder of this gene or with short-coupled or idiopathic ventricular fibrillation
  • Anyone pregnant, breastfeeding or seeking conception
  • Anyone with a chronic pain condition
Key Interactions
Theoretical (inferred from mechanism)
  • Selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline)
  • Methylxanthines (caffeine, theophylline)
  • Riluzole
  • Mood stabilizers (lithium, valproate, carbamazepine)
  • Volatile anesthetics (sevoflurane, isoflurane, halothane)
  • Polyunsaturated fatty acids (the omega-3 fats EPA and DHA from fish oil, and α-linolenic acid)
  • Quercetin
  • Insulin secretagogues (sulfonylureas such as glipizide, meglitinides such as repaglinide)
  • Other peptides stacked in self-experimentation (e.g., Selank, Semax)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Infection, contamination and mislabeled material
  • Speculative: Lower seizure threshold; cardiac rhythm disturbance; heightened pain sensitivity; reversal of effect with dose; fat gain and impaired glucose tolerance; worse outcome from cerebral ischemia; immune response to a synthetic peptide

Monitoring

Marker Target Why
Resting heart rate and rhythm (electrocardiogram) 60–100 beats per minute Safety check: new bradycardia or sinus pause would stop use
Fasting plasma glucose 70–99 mg/dL Safety check: hypoglycemia would stop use
Glycated hemoglobin (HbA1c) 4.0–5.6% Marker the intervention is expected to change, in either direction
Structured depression score (e.g., PHQ-9) No established target — track change from the individual's own baseline Marker the intervention is expected to change: mood is the claimed effect

Cadence: No cadence rests on evidence; baseline before any use, then the rhythm and glucose measures at 1 week and 4 weeks and the mood score weekly, with any new bradycardia, pause, seizure, hypoglycemia or neurological symptom treated as a reason to stop

Qualitative Assessment

  • Mood and motivation, recorded daily rather than recalled
  • Energy and daytime sleepiness
  • Sleep onset and continuity
  • Pain threshold and any new or worsened pain
  • Cognitive clarity and working memory in ordinary tasks
  • Injection-site appearance, where any injection is used